Evidence map›Paper›PMID 36721911›Full record

ArticleCerebral cortex (New York, N.Y. : 1991)2023

Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer's disease.

Nick Corriveau-Lecavalier, Leland R Barnard, Jeyeon Lee, Ellen Dicks, Hugo Botha, Jonathan Graff-Radford, Mary M Machulda, Bradley F Boeve, David S Knopman, Val J Lowe and 3 more

Abstract read
In one paragraph

Article in Cerebral cortex (New York, N.Y. : 1991), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Can Frontal Assessment Battery Discriminate between Patients with Alzheimer's and Frontotemporal Dementia?Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Atypical Presentations of Alzheimer Disease.Continuum (Minneapolis, Minn.) · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nick Corriveau-LecavalierDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Leland R BarnardDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Jeyeon LeeDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Ellen DicksDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-4807-9833

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG041851NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786
6 · The paper itself

Abstract

Dysexecutive Alzheimer's disease (dAD) manifests as a progressive dysexecutive syndrome without prominent behavioral features, and previous studies suggest clinico-radiological heterogeneity within this syndrome. We uncovered this heterogeneity using unsupervised machine learning in 52 dAD patients with multimodal imaging and cognitive data. A spectral decomposition of covariance between FDG-PET images yielded six latent factors ("eigenbrains") accounting for 48% of variance in patterns of hypometabolism. These eigenbrains differentially related to age at onset, clinical severity, and cognitive performance. A hierarchical clustering on the eigenvalues of these eigenbrains yielded four dAD subtypes, i.e. "left-dominant," "right-dominant," "bi-parietal-dominant," and "heteromodal-diffuse." Patterns of FDG-PET hypometabolism overlapped with those of tau-PET distribution and MRI neurodegeneration for each subtype, whereas patterns of amyloid deposition were similar across subtypes. Subtypes differed in age at onset and clinical severity where the heteromodal-diffuse exhibited a worse clinical picture, and the bi-parietal had a milder clinical presentation. We propose a conceptual framework of executive components based on the clinico-radiological associations observed in dAD. We demonstrate that patients with dAD, despite sharing core clinical features, are diagnosed with variability in their clinical and neuroimaging profiles. Our findings support the use of data-driven approaches to delineate brain-behavior relationships relevant to clinical practice and disease physiology.

Indexed as

Alzheimer DiseaseBrainFluorodeoxyglucose F18HumansMagnetic Resonance ImagingNeuroimagingPositron-Emission TomographyFluorodeoxyglucose F18behavioral neurologydysexecutive Alzheimer’s diseaseFDG-PETmachine learningneuropsychology

Identifiers

PMID36721911
PMCPMC10233237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.